Vaira Leimane

6.8k total citations · 1 hit paper
30 papers, 2.4k citations indexed

About

Vaira Leimane is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Vaira Leimane has authored 30 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 22 papers in Epidemiology and 9 papers in Surgery. Recurrent topics in Vaira Leimane's work include Tuberculosis Research and Epidemiology (29 papers), Pneumonia and Respiratory Infections (12 papers) and Mycobacterium research and diagnosis (10 papers). Vaira Leimane is often cited by papers focused on Tuberculosis Research and Epidemiology (29 papers), Pneumonia and Respiratory Infections (12 papers) and Mycobacterium research and diagnosis (10 papers). Vaira Leimane collaborates with scholars based in United States, Latvia and Estonia. Vaira Leimane's co-authors include Vija Riekstiņa, Timothy H. Holtz, Charles D. Wells, Kayla F. Laserson, Lorna E. Thorpe, Ģirts Šķenders, J. Peter Cegielski, Carole D. Mitnick, Martin P. Grobusch and Eduardo Gotuzzo and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

Vaira Leimane

29 papers receiving 2.3k citations

Hit Papers

Multidrug-Resistant Tuberculosis and Culture Conversion w... 2014 2026 2018 2022 2014 100 200 300 400 500

Peers

Vaira Leimane
Lawrence Geiter United States
Karin Weyer Switzerland
Thuli Mthiyane South Africa
Iqbal Master South Africa
Stefan Goldberg United States
Jennifer Hughes South Africa
Gregory P. Bisson United States
Lawrence Geiter United States
Vaira Leimane
Citations per year, relative to Vaira Leimane Vaira Leimane (= 1×) peers Lawrence Geiter

Countries citing papers authored by Vaira Leimane

Since Specialization
Citations

This map shows the geographic impact of Vaira Leimane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vaira Leimane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vaira Leimane more than expected).

Fields of papers citing papers by Vaira Leimane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vaira Leimane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vaira Leimane. The network helps show where Vaira Leimane may publish in the future.

Co-authorship network of co-authors of Vaira Leimane

This figure shows the co-authorship network connecting the top 25 collaborators of Vaira Leimane. A scholar is included among the top collaborators of Vaira Leimane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vaira Leimane. Vaira Leimane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kukša, Līga, Vija Riekstiņa, Vaira Leimane, et al.. (2014). Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action. 4(Supplement 2). S47–S53. 20 indexed citations
2.
Diacon, Andreas H., Alexander S. Pym, Martin P. Grobusch, et al.. (2014). Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. New England Journal of Medicine. 371(8). 723–732. 505 indexed citations breakdown →
3.
Miller, Thaddeus L., Andra Cīrule, Fernando A. Wilson, et al.. (2013). The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia. Cost Effectiveness and Resource Allocation. 11(1). 9–9. 6 indexed citations
4.
Dalton, Tracy, Peter Cegielski, Somsak Akksilp, et al.. (2012). Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. The Lancet. 380(9851). 1406–1417. 163 indexed citations
5.
Danilovitš, Manfred, Lea Pehme, Ģirts Šķenders, et al.. (2012). Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. European Respiratory Journal. 41(6). 1393–1400. 233 indexed citations
6.
Kurbatova, Ekaterina V., Victoria M. Gammino, Jaime Bayona, et al.. (2012). Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 16(10). 1335–1343. 65 indexed citations
7.
Kurbatova, Ekaterina V., A. Taylor, Victoria M. Gammino, et al.. (2012). Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 92(5). 397–403. 115 indexed citations
8.
Gammino, Victoria M., A. Taylor, Michael Rich, et al.. (2011). Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. The International Journal of Tuberculosis and Lung Disease. 15(10). 1315–1322. 11 indexed citations
9.
Leimane, Vaira, et al.. (2010). Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. European Respiratory Journal. 36(3). 584–593. 64 indexed citations
10.
Podewils, Laura Jean, et al.. (2010). Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients. Epidemiology and Infection. 139(1). 113–120. 76 indexed citations
11.
Bloss, Emily, et al.. (2010). Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.. PubMed. 14(3). 275–81. 79 indexed citations
12.
Dravniece, Gunta, K. P. Cain, Timothy H. Holtz, et al.. (2009). Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis: Table 1—. European Respiratory Journal. 34(1). 180–183. 38 indexed citations
13.
Leimane, Vaira. (2007). Treatment and management of MDR-TB in Latvia. Europe PMC (PubMed Central). 4 indexed citations
14.
Leimane, Vaira. (2007). Treatment and management of MDR-TB in Latvia. Bulletin of the World Health Organization. 85(5). 393–394. 4 indexed citations
15.
Rich, Michael, Rajesh Gupta, Jaime Bayona, et al.. (2006). Multidrug-resistant Tuberculosis Management in Resource-limited Settings. Emerging infectious diseases. 12(7). 1389–1397. 134 indexed citations
16.
Leimane, Vaira, et al.. (2006). Tuberculosis control in Latvia: integrated DOTS and DOTS-plus programmes. Eurosurveillance. 11(3). 17–18. 18 indexed citations
17.
Leimane, Vaira, Vija Riekstiņa, Timothy H. Holtz, et al.. (2005). Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. The Lancet. 365(9456). 318–326. 216 indexed citations
18.
Šķenders, Ģirts, Alicia M. Fry, Beverly Metchock, et al.. (2005). Multidrug-resistant Tuberculosis Detection, Latvia. Emerging infectious diseases. 11(9). 1461–1463. 27 indexed citations
19.
Gupta, Rajesh, et al.. (2004). Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.. PubMed. 8(11). 1382–4. 147 indexed citations
20.
Morozova, Irina А., et al.. (2003). Impact of the growing HIV-1 epidemic on multidrug-resistant tuberculosis control in Latvia.. PubMed. 7(9). 903–6. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026